Abstract
Semaphorins (Semas), a family of evolutionarily conserved secreted and transmembrane proteins, were initially identified as axon guidance regulators and have since been implicated in the development of a number of other tissues. Sema signaling also regulates a variety of processes that are linked to cancer (i.e. metastasis, cell migration, cell growth). The mechanisms by which Sema signaling regulates axonogenesis and tumorigenesis are strikingly similar, making advances in either field applicable to the alternate discipline. Here, recent advances in understanding the roles of Semas in development and cancer, as well as the therapeutic potential for targeting this signaling pathway in human cancers, are reviewed.
Keywords: Semaphorin, Plexin, axon guidance, cancer, development
Current Drug Targets
Title: Semaphorins at the Interface of Development and Cancer
Volume: 10 Issue: 7
Author(s): E. Flannery and M. Duman-Scheel
Affiliation:
Keywords: Semaphorin, Plexin, axon guidance, cancer, development
Abstract: Semaphorins (Semas), a family of evolutionarily conserved secreted and transmembrane proteins, were initially identified as axon guidance regulators and have since been implicated in the development of a number of other tissues. Sema signaling also regulates a variety of processes that are linked to cancer (i.e. metastasis, cell migration, cell growth). The mechanisms by which Sema signaling regulates axonogenesis and tumorigenesis are strikingly similar, making advances in either field applicable to the alternate discipline. Here, recent advances in understanding the roles of Semas in development and cancer, as well as the therapeutic potential for targeting this signaling pathway in human cancers, are reviewed.
Export Options
About this article
Cite this article as:
Flannery E. and Duman-Scheel M., Semaphorins at the Interface of Development and Cancer, Current Drug Targets 2009; 10 (7) . https://dx.doi.org/10.2174/138945009788680383
DOI https://dx.doi.org/10.2174/138945009788680383 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Breast Cancer Resistance Protein: A Potential Therapeutic Target for Cancer
Current Drug Targets Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry Chemical Consequences of Radioactive Decay and their Biological Implications
Current Radiopharmaceuticals subject Index To Volume 2
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target
Current Vascular Pharmacology Late Effects in Survivors of Childhood CNS Tumors: Review of Results From the Two Largest Survivorship Cooperative Groups
Current Cancer Therapy Reviews Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Current Pharmaceutical Design MicroRNAs and Cancer; an Overview
Current Pharmaceutical Biotechnology Anti-VEGF Mediated Immunomodulatory Role of Phytochemicals: Scientific Exposition for Plausible HCC Treatment
Current Drug Targets Nanoparticle-Delivered Quercetin for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Antibody-Targeted RNase Fusion Proteins (ImmunoRNases) for Cancer Therapy
Current Pharmaceutical Biotechnology <i>In Vitro</i> Effects of Propofol on Cytotoxic, Apoptotic and PI3K-Akt Signaling Pathway Genes on Brain Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and <i>in vitro</i> Studies
Current Cancer Drug Targets Beta-adrenergic Signaling: Complexities and Therapeutic Relevance to Heart Failure
Current Signal Transduction Therapy Fluorescence Molecular Imaging of Small Animal Tumor Models
Current Molecular Medicine Insights into Ecto-5’-Nucleotidase as a New Target for Cancer Therapy: A Medicinal Chemistry Study
Current Medicinal Chemistry Role of Inflammatory Mediators in Angiogenesis
Current Drug Targets - Inflammation & Allergy Serum Biochemical Markers of Brain Injury
Mini-Reviews in Medicinal Chemistry Targeted Cancer Therapeutics: Biosynthetic and Energetic Pathways Characterized by Metabolomics and the Interplay with Key Cancer Regulatory Factors
Current Pharmaceutical Design